2014-04-15 16:07:07 UTC

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for HCV with Cirrhosis

April 17, 2014

Fred Poordad and colleagues report in New England Journal of Medicine that multitargeted therapy with the use of three new interferon-free, antiviral agents and ribavirin resulted in high rates of sustained virologic response.

Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. Fred Poordad and colleagues evaluated the interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the NS5A inhibitor ombitasvir (ABT-267), the nonnucleoside polymerase inhibitor dasabuvir (ABT-333), and ribavirin in an open-label phase 3 trial involving previously untreated and previously treated adults with HCV genotype 1 infection and compensated cirrhosis. They report in New England Journal of Medicine that multitargeted therapy with the use of three new interferon-free, antiviral agents and ribavirin resulted in high rates of sustained virologic response. Drug discontinuations due to adverse events were infrequent. 

New England Journal of Medicine 2014: DOI: 10.1056/NEJMoa1402869

More on Cirrhosis

Blog: Special 15th Anniversary Collection from Clinical Gastroenterology and Hepatology

Oct. 11, 2017

Celebrate this milestone with a look back at landmark articles, commentaries and reviews. Read more on the AGA Journals blog.

Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis

Oct. 11, 2017

Statin use is probably associated with lower risk of hepatic decompensation and mortality, and might reduce portal hypertension, in patients with CLDs.

Cirrhosis Presenting as Cutaneous Calciphylaxis

Oct. 11, 2017

A 73-year-old woman with a history of hypertension presented with a 3-month history of a painful, non-healing right calf ulcer and 2–3 weeks of painful, dusky purple patches on the right thigh.